Market research
MXCT.LSE MaxCyte, Inc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 162M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.04
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US57777K1060
- Market cap
- 162M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.04
About
About MaxCyte, Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MXCT.LSE discussion.
5 years, 4 months ago
MaxCyte, Inc is currently in a long term uptrend where the price is trading 41.8% above its 200 day moving average.
From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 29.7.
Based on the above factors, MaxCyte, Inc gets an overall score of 2/5.